The evidence-based medicine paradigm: Where are we 20 years later? Part 2

Canadian Journal of Neurological Sciences

Volumn 40, Issue 4, 2013, Pages 475-481

  Seshia, Shashi S ^a   Young, G Bryan ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; PHENYTOIN; PLACEBO;

CLINICAL DECISION MAKING; CLINICAL RESEARCH; COGNITION; DIAGNOSTIC TEST; ETHICS; EVIDENCE BASED MEDICINE; GOLD STANDARD; HUMAN; MEASUREMENT; NEUROSCIENCE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TEMPORAL LOBE EPILEPSY;

EID: 84879365021     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100014554     Document Type: Review

References (80)

1. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: How will we ever keep up? PLoS Med. 2010;7: E1000326
2. Straus SE, Glasziou P, Richardson WS, Haynes RB. Evidencebased Medicine; 4th ed. Toronto: Churchill Livingstone Elsevier, 2011
3. Montori VM, Guyatt GH. Progress in evidence-based medicine. JAMA. 2008;300: 1814-6.
4. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidencebased medicine". Am J Med. 1997;103: 529-35
5. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152: 726-32
6. Hirst A, Altman DG. Are peer reviewers encouraged to use reporting guidelines? A survey of 116 health research journals. PLoS One. 2012;7: E35621
7. CONSORT group. [cited 2012 Dec 13]. Available from: Http: //www.consort-statement.org/
8. Berwanger O, Ribeiro RA, Finkelsztejn A, et al. The quality of reporting of trial abstracts is suboptimal: Survey of major general medical journals. J Clin Epidemiol. 2009;62: 387-92
9. Shukralla AA, Tudur-Smith C, Powell GA, Williamson PR, Marson AG. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res. 2011;97: 20-9.
10. Assadi R, Zarghi N, Sapehri Shamloo A, Nikooiyan Y. Evidencebased abstracts: What research summaries should contain to support evidence-based medicine. Int J Evid Based Healthc. 2012;10: 154-8.
11. DeMauro SB, Giaccone A, Kirpalani H, Schmidt B. Quality of reporting of neonatal and infant trials in high-impact journals. Pediatrics. 2011;128: E639-44
12. Kiehna EN, Starke RM, Pouratian N, Dumont AS. Standards for reporting randomized controlled trials in neurosurgery. J Neurosurg. 2011;114: 280-5.
13. Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ. 2006;174: 469-76
14. STARD. [Update April 2008; cited 2012 Dec 13]. Available from: Http: //www.stard-statement.org/
15. Bossuyt PM. STARD statement: Still room for improvement in the reporting of diagnostic accuracy studies. Radiology. 2008;248: 713-4.
16. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336: 1106-10 (Pubitemid 351731739)
17. Hess AS, Shardell M, Johnson JK, et al. Methods and recommendations for evaluating and reporting a new diagnostic test. Eur J Clin Microbiol Infect Dis. 2012;31: 2111-6.
18. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328: 1490
19. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4: 38
20. Atkins D, Briss PA, Eccles M, et al. Systems for grading the quality of evidence and the strength of recommendations II: Pilot study of a new system. BMC Health Serv Res. 2005;5: 25
21. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336: 924-6. (Pubitemid 351632017)
22. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336: 995-8. (Pubitemid 351656090)
23. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336: 1049-51
24. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ. 2008;336: 1170-3. (Pubitemid 351809277)
25. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64: 383-94
26. Thornton J, Alderson P, Tan T, et al. Introducing GRADE across the NICE clinical guideline program. J Clin Epidemiol. 2013 Feb;66 (2).: 124-31
27. Nakagawa TA, Ashwal S, Mathur M, Mysore M, Committee For Determination Of Brain Death In Infants Children. Guidelines for the determination of brain death in infants and children: An update of the 1987 task force recommendations-executive summary. Ann Neurol. 2012;71: 573-85
28. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39: S1-59
29. Goldenberg MJ, Borgerson K, Bluhm R. The nature of evidence in evidence-based medicine: Guest editors' introduction. Perspect Biol Med. 2009;52: 164-7.
30. Upshur R. Making the grade: Assuring trustworthiness in evidence. Perspect Biol Med. 2009;52: 264-75
31. Hartling L, Fernandes RM, Seida J, Vandermeer B, Dryden DM. From the trenches: A cross-sectional study applying the GRADE tool in systematic reviews of healthcare interventions. PLoS One. 2012;7: E34697
32. Centre for Evidence-Based Medicine, University of Oxford. Oxford, UK. [cited 2012 Dec 12]. Available from: Http: //www.cebm.net/
33. Oricha BS, Yauri MB. Uncertainty principle versus clincal equipoise in clinical trials in Sub-Saharan Africa: Are they really tenable? Ann African Med. 2003;2(2).: 99-100
34. Jadad AR, Enkin MW. Randomized controlled trials. Oxford, UK: Blackwell Publishing BMJI Books, 2007
35. Burneo JG, Demaerschalk BM, Jenkins ME, editors. Neurology: An evidence-based approach. New York: Springer 2012
36. Wiebe S, Demaerschalk B. Evidence based care in the neurosciences. Can J Neurol Sci. 2002;29: 115-9.
37. Gronseth G, French J. Practice parameters and technology assessments: What they are, what they are not, and why you should care. Neurology. 2008;71: 1639-43
38. French J, Gronseth G. Lost in a jungle of evidence: We need a compass. Neurology. 2008;71: 1634-8.
39. Brigo F. New anti-epileptic drugs: Overcoming the limits of randomised controlled trials. Int J Evid Based Healthc. 2011;9: 440-3.
40. Mattson RH, Cramer JA, Delgado Escueta AV, Smith DB, Collins JF. A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. Neurology. 1983;33: 14-25 (Pubitemid 13147838)
41. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313: 145-51 (Pubitemid 15047456)
42. Anonymous. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia. 1998;39: 952-9.
43. Wiebe S, Blume WT, Girvin JP, Eliasziw M, Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345: 311-8.
44. Barnett HJM. Experiences with the execution of intercultural, intercontinental trials - Part I. Can J Neurol Sci. 2013;40: 324-9.
45. Goodin DS, Reder AT. Evidence-based medicine: Promise and pitfalls. Mult Scler. 2012;18: 947-8.
46. Gronseth GS, Ashman E. The AAN response to evidence-based medicine: Promise and pitfalls. Mult Scler. 2012;18: 949-50
47. Mendelson AA, Gillis C, Henderson WR, Ronco JJ, Dhingra V, Griesdale DE. Intracranial pressure monitors in traumatic brain injury: A systematic review. Can J Neurol Sci. 2012;39: 571-6.
48. Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011;364: 1493-502
49. Honeybul S, Ho KM. The influence of clinical evidence on surgical practice. J Eval Clin Pract 2012; May 8 [Epub ahead of print].PMID: 22568805
50. Honeybul S, Ho KM, Lind CR. What Can Be Learned from the DECRA Study. World Neurosurg. 2013;79: 159-61
51. Iaccarino C, Schiavi P, Servadei F. Decompressive Craniectomies: Time to Discuss Not the DECRA Study but the Comments to the DECRA Study. World Neurosurg. 2013;79: 78-9.
52. Hutchinson PJ, Timofeev I, Kolias AG, et al. Decompressive craniectomy for traumatic brain injury: The jury is still out. Br J Neurosurg. 2011;25: 441-2.
53. Lemcke J. Taming a tyrannosaur: The decompressive craniectomy for traumatic brain injury has to become an evidence-based procedure. Eur J Neurol. 2011;18: 543-4.
54. Chi JH. Craniectomy for traumatic brain injury: Results from the DECRA trial. Neurosurgery. 2011;68: N19-20
55. Torres R. DECRA.Where do we go from here? Surg Neurol Int. 2012;3: 54
56. Kitagawa RS, Bullock MR. Lessons from the DECRA Study. World Neurosurg. 2013;79: 82-4.
57. Cooper DJ, Rosenfeld JV, Wolfe R. DECRA Investigators' Response to "The Future of Decompressive Craniectomy for Diffuse Traumatic Brain Injury" by Honeybul et al. J Neurotrauma. 2012;29: 2595-6.
58. Drazen JM. Believe the data. N Engl J Med. 2012;367: 1152-3.
59. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268: 2420-5.
60. Kahlon G, Mansi IA, Banks DE. Educating medical students in evidence-based medicine: What we should expect as a starting point for our house officers. South Med J. 2012;105: 184-8.
61. Booth A. Evidence-based practice: Triumph of style over substance? Health Info Libr J. 2011;28: 237-41
62. Rawlins M. De testimonio: On the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372: 2152-61
63. Rawlins MD. De Testimonio: On the evidence for decisions about the use of therapeutic interventions. London, UK: Royal College of Physicians, 2008
64. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13: 217-24
65. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn't. BMJ. 1996;312: 71-2.
66. Mills JL. Data torturing. N Engl J Med. 1993;329: 1196-9. (Pubitemid 23295466)
67. Greenhalgh T. How to read a paper. Statistics for the nonstatistician. II: "Significant" relations and their pitfalls. BMJ. 1997;315: 422-5. (Pubitemid 27346047)
68. Senn S, Julious S. Measurement in clinical trials: A neglected issue for statisticians? Stat Med. 2009;28: 3189-209
69. Hartling L, Hamm M, Milne A, et al. Validity and inter-rater reliability testing of quality assessment instruments. Rockville (MD).: Agency for health care research and policy, US department of health and human services, 2012
70. Matcham J, Julious S, Pyke S, et al. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. Pharm Stat. 2011;10: 70-3.
71. Mansi BA, Clark J, David FS, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: A joint journal and pharmaceutical industry perspective. Mayo Clin Proc. 2012;87: 424-9.
72. Drazen JM. Transparency for Clinical Trials - The TEST Act. N Engl J Med. 2012;367(9).: 863-4.
73. Strech D, Littmann J. Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data. Trials. 2012;13: 100
74. Kesselheim AS, Wang B, Studdert DM, Avorn J. Conflict of interest reporting by authors involved in promotion of off-label drug use: An analysis of journal disclosures. PLoS Med. 2012;9: E1001280
75. Crosskerry P, Nimmo GR. Better clinical decision making and reducing diagnostic error. J R Coll Physicians Edinb. 2011;41: 155-62
76. Croskerry P, Abbass AA, Wu AW. How doctors feel: Affective issues in patients' safety. Lancet. 2008;372: 1205-6.
77. Croskerry P. Context is everything or how could I have been that stupid? Healthc Q. 2009;12 Spec No Patient: E171-6.
78. Croskerry P. A universal model of diagnostic reasoning. Acad Med. 2009;84: 1022-8.
79. Crosskerry P. Perspectives on diagnostic failure and patient safety. Healthc Q. 2012;15 suppl: 50-6.
80. Hill AB. Medical ethics and controlled trials. Br Med J. 1963;1: 1043-9.